Peptidream Inc., of Kawasaki, Japan, signed a multiprogram collaborative research agreement with Osaka, Japan-based Shionogi & Co. Ltd. for the discovery and development of a series of blood-brain barrier-penetrating peptide drug-conjugates (PDCs). Read More
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is launching a pilot good clinical practices (GCP) program in the hopes of launching a routine GCP inspections program. Read More
PERTH, Australia – Australia's Neuclone Pharmaceuticals Ltd. is developing a broad pipeline of biosimilars, and it plans on being a big disrupter to the global pharma market. Read More
HONG KONG – With a focus on precision drug delivery, Napajen Pharma Inc. has developed a platform technology that enables stable and selective delivery of oligonucleotide compounds to immune cells, with sights set on treating immune-related conditions, such as autoimmune diseases and cancer, as well as developing transplants and vaccines. Read More
PERTH, Australia – Like many Aussie companies, Invion Ltd. started out with some assets that it had a difficult time progressing forward, and it ended up remaking itself into a completely different company with new assets. Now, Melbourne-headquartered Invion plans to enter the clinic early this year with a photosensitizer therapy to treat melanoma. Read More
HONG KONG – Roughly half a year after starting phase I development, Chinese biosimilars maker Bio-Thera Solutions Ltd. moved BAT-1806, its biosimilar referencing Genentech Inc.'s Roactemra (tocilizumab) for rheumatoid arthritis, into a global phase III trial. Read More
PERTH, Australia – Stress is often a factor that contributes to many conditions ranging from psoriasis to irritable bowel syndrome, but it also has an effect on the brain, and recent evidence has shown that stress may be involved in accelerating the onset of Alzheimer's disease as well as worsening the course of the disease. Read More
HONG KONG – CAR T biotech Immunochina Pharmaceuticals Co. Ltd. raised ¥140 million (US$20.7 million) in a series C funding round to further develop its lead CAR T therapy targeting CD19, known as IM-19, to compete with Novartis AG's Kymriah (tisagenlecleucel). Read More
In every type of financing, from IPOs and follow-on public offerings to private placements and venture capital rounds, the med-tech industry produced more money and completed more financings in 2018 than the prior year, reflecting the same significant jump in activity seen with its biopharma counterpart. Read More
